2027 ICD-10-CM Diagnosis Code C53.9Malignant neoplasm of cervix uteri, unspecified

ICD-10-CM Codes›C00–D49›C51-C58›C53

ICD-10-CM C53.9
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

C53.9 is a billable ICD-10-CM diagnosis code for malignant neoplasm of cervix uteri, unspecified. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 731 through 733, 754 through 756. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Female reproductive system cancers - cervix.

For Medicare Advantage risk adjustment, C53.9 maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers) under the V28 model, adding a risk factor of about 0.363 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
C53.9
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of cervix uteri, unspecified
Short Description
Malignant neoplasm of cervix uteri, unspecified
Same as the full description in the CMS dataset.
Parent Code
Malignant neoplasm of cervix uteri

Code Classification

ChapterC00–D49Neoplasms
SectionC51-C58Malignant neoplasms of female genital organs
CategoryC53Malignant neoplasm of cervix uteri
This CodeC53.9Malignant neoplasm of cervix uteri, unspecified

Medicare Risk Adjustment (HCC)Billing

C53.9 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 22— Bladder, Colorectal, and Other Cancers
Payment HCC · PY 2027 one of 126 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.363
community, non-dual, aged · ranges 0.314–0.410 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, HCC 20, and HCC 21
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 11
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 11 · ESRD (V21): HCC 11 · ESRD (V24): HCC 11
ESRD V21 weights: 0.076 dialysis, 0.284–0.298 functioning graft · ESRD V24 weights: 0.059 dialysis, 0.257–0.362 functioning graft
Part D (RxHCC)
Not mapped
C53.9 does not risk-adjust in the RxHCC prescription drug model

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Adenocarcinoma of cervix
  • Adenoid basal carcinoma of cervix uteri
  • Adenoid cystic carcinoma of cervix uteri
  • Adenoma malignum
  • Adenosarcoma of cervix uteri
  • Adenosarcoma of uterus
  • Adenosquamous carcinoma of cervix
  • Carcinoma of cervix
  • Carcinoma of uterine cervix, invasive
  • Carcinosarcoma of cervix uteri
  • Carcinosarcoma of uterus
  • Glassy cell carcinoma of cervix uteri
  • Invasive carcinoma of uterine cervix co-occurrent with human immunodeficiency virus infection
  • Leiomyosarcoma of cervix uteri
  • Leiomyosarcoma of uterus
  • Local recurrence of malignant neoplasm of cervix uteri
  • Malignant germ cell neoplasm of cervix uteri
  • Malignant neoplasm involving left fallopian tube by direct extension from uterine cervix
  • Malignant neoplasm involving right fallopian tube by direct extension from uterine cervix
  • Malignant neoplasm involving urinary bladder by direct extension from uterine cervix
  • Malignant neoplasm of cervix uteri
  • Malignant neoplastic disease co-occurrent with human immunodeficiency virus infection
  • Malignant tumor involving an organ by direct extension from uterine cervix
  • Malignant tumor involving left ovary by direct extension from uterine cervix
  • Malignant tumor involving rectum by direct extension from uterine cervix
  • Malignant tumor involving right ovary by direct extension from uterine cervix
  • Malignant tumor involving uterine corpus by direct extension from uterine cervix
  • Malignant tumor involving vagina by direct extension from uterine cervix
  • Malignant tumor involving vulva by direct extension from uterine cervix
  • Peripheral neuroectodermal neoplasm of cervix uteri
  • Peripheral neuroectodermal tumor
  • Primary adenocarcinoma of cervix uteri
  • Primary adenoid basal carcinoma of cervix uteri
  • Primary adenoid cystic carcinoma of cervix uteri
  • Primary adenosarcoma of cervix uteri
  • Primary adenosarcoma of uterus
  • Primary adenosquamous carcinoma of cervix
  • Primary adenosquamous cell carcinoma
  • Primary carcinoma of cervix
  • Primary carcinoma of uterine cervix, invasive
  • Primary carcinosarcoma of cervix uteri
  • Primary carcinosarcoma of uterus
  • Primary glassy cell carcinoma of cervix uteri
  • Primary malignant neoplasm of uterine cervix
  • Primary papillary carcinoma of cervix uteri
  • Primary poorly differentiated endocrine carcinoma of cervix uteri
  • Primary primitive neuroectodermal tumor
  • Primary primitive neuroectodermal tumor of cervix uteri
  • Primitive neuroectodermal tumor of cervix uteri
  • Rhabdomyosarcoma of cervix uteri
  • Squamous cell carcinoma of cervix

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to C53.9: its own notes plus those printed at C53, block C51-C58, and Chapter 2. A note printed at a category, block or chapter applies to every code under it.

Includes

Further defines, or gives examples of, the content of the category.

From Block C51-C58 Malignant neoplasms of female genital organs applies to 36 codes
  • malignant neoplasm of skin of female genital organs

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From C53 Malignant neoplasm of cervix uteri applies to 4 codes
  • carcinoma in situ of cervix uteri (D06.-)

Notes

General instructions on how these codes are used.

From Chapter 2 (C00-D49) Neoplasms applies to 1,730 codes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name C53.9, its category, or a range that includes it.

Applicable To 2

These notes mention C53.9.

  • Z80.4 Family history of malignant neoplasm of genital organs
    Conditions classifiable to C51-C63 names C51-C63, which includes this code
  • Z85.4 Personal history of malignant neoplasm of genital organs
    Conditions classifiable to C51-C63 names C51-C63, which includes this code

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO032
Female reproductive system cancers - cervix
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Malignant Cervical Neoplasm

    a primary or metastatic malignant neoplasm involving the cervix.

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary
Malig.
Secondary
Ca
in situ
BenignUncertainUnspec.
cervix (cervical) (uteri) (uterus)C53.9C79.82D06.9D26.0D39.0D49.59
uterus, uteri, uterine › cervixC53.9C79.82D06.9D26.0D39.0D49.59

Patient EducationClinical

Cervical Cancer

Cervical cancer is cancer that starts in the cells of the cervix. The cervix is part of the female reproductive system. It is the lower, narrow end of the uterus (womb), which opens into the vagina (birth canal).

The full article covers:

  • What is cervical cancer?
  • What causes cervical cancer?
  • Who is more likely to develop cervical cancer?
  • What are the symptoms of cervical cancer?
  • How is cervical cancer diagnosed?
  • What are the treatments for cervical cancer?
  • Can cervical cancer be prevented?
  • What is Cervical Cancer?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C53.9 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
180.9 Mal neo cervix uteri NOS
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About C53.9Overview

What is the ICD-10 code for malignant neoplasm of cervix uteri, unspecified?

The ICD-10-CM code for malignant neoplasm of cervix uteri, unspecified is C53.9 (sometimes written as C539). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is C53.9 (Malignant neoplasm of cervix uteri) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of cervix uteri, unspecified on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does C53.9 group to?

When malignant neoplasm of cervix uteri, unspecified is the principal diagnosis on an inpatient stay, it groups to MS-DRG 732, 755, 756, 754, 733, 731, with relative weights from 0.8583 to 3.5462 depending on complications. Higher weights mean higher Medicare reimbursement.

Can C53.9 be reported with a code from D06?

Not as a rule. The Excludes1 note at C53, which applies to C53.9, lists "carcinoma in situ of cervix uteri (D06.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

What is the ICD-9 equivalent of C53.9?

Under the General Equivalence Mappings, malignant neoplasm of cervix uteri, unspecified converts to ICD-9-CM 180.9 (mal neo cervix uteri NOS). The mapping is a direct match.

What HCC is C53.9?

C53.9 (malignant neoplasm of cervix uteri, unspecified) maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers), commonly written as HCC 22, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 11 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.

Does C53.9 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, C53.9 adds a risk adjustment factor of about 0.363 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.314 to 0.410 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, and HCC 21) supersedes it when both are reported. See the full factor table on the HCC 22 category page.